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The pharmacophore concept is a fundamental cornerstone in drug discovery, playing a critical role in 37 
determining the success of in silico techniques, such as virtual screening and 3D-QSAR studies. The 38 
reliability of these approaches is influenced by the quality of the physicochemical descriptors used to 39 
characterize the chemical entities. In this context, a pivotal role is exerted by lipophilicity, which is a major 40 
contribution to host-guest interaction and ligand binding affinity. Several approaches have been undertaken 41 
to account for the descriptive and predictive capabilities of lipophilicity in 3D-QSAR modelling. Recent 42 
efforts encode the use of quantum mechanical-based descriptors derived from continuum solvation models, 43 
which open novel avenues for gaining insight into structure-activity relationships studies. 44 
 45 
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1. The pharmacophore concept and its application in drug design. 70 
Almost all processes of life are determined by the recognition between biomolecules, a process dictated by 71 
the chemical complementarity between the interacting partners [1]. An effective characterization of the 72 
chemical features associated to the structure of both "host" and "guest" is necessary for disclosing the key 73 
molecular determinants implicated in the formation of the host-guest complex. In drug discovery studies 74 
addressing the interaction of small molecules (ligands) with macromolecular receptors, these determinants 75 
are generally encoded under the concept of pharmacophore. A simple and intuitive definition can be 76 
attributed to Paul Ehrlich, since this concept can be related to “a molecular framework that carries (phoros) 77 
the essential features responsible for a drug’s (pharmacon) biological activity” [2]. Nevertheless, Ehrlich did 78 
not use the term pharmacophore in his papers, where the terms haptophore and toxophore were adopted [3]. 79 
Instead, the modern concept of pharmacophore evolved from the identification of "chemical groups" to the 80 
definition as "patterns of abstract features in space" by Schueler [4], reflected in early models depicting key 81 
features for biological activity that must satisfy certain geometrical relationships [5, 6], and the development 82 
of the first pharmacophore pattern recognition programs [7]. Thus, according to the International Union of 83 
Pure and Applied Chemistry (IUPAC), a pharmacophore "does not represent a real molecule or a real 84 
association of functional groups, but a purely abstract concept that accounts for the common molecular 85 
interaction capacities of a group of compounds towards their target structure", being the largest common 86 
denominator shared by a set of active molecules [8].  87 
This evolution has been accompanied by the progressive refinements triggered by advances in molecular 88 
descriptors and computational methods seen in the last 30 years, since a variety of in silico techniques have 89 
exploited the pharmacophore concept. This is exemplified by virtual screening (VS) studies of large 90 
molecular databases performed to identify new promising compounds according to their similarity to a given 91 
privileged template, which should contain reference physicochemical features relevant for biological activity 92 
[9-11]. Molecular/chemical (global/local) similarity is a subjective concept since it depends on the specific 93 
details of the methodological approach, the nature of the molecular features relevant for similarity 94 
assessment, and the definition of the similarity function [12]. A sensitive and effective estimation of 95 
molecular similarity is a fundamental pre-requisite for the identification of potential leads starting from a 96 
chemical reference, which represents the paradigm of virtual screening. 97 
Another successful application of the pharmacophore concept is linked to 3D quantitative structure-activity 98 
relationships (3DQSAR) [13], such as CoMFA [14], CoMSIA [15] and GRID/GOLPE [16]. These methods 99 
permit to identify a pharmacophore from the relationships between the biological activities of a set of aligned 100 
molecules and the projection of selected physicochemical descriptors into the surrounding space, leading to 101 
the disclosure of regions favourable or not to the bioactivity of compounds. 3D-QSAR approaches are also 102 
used to model ADME(T) properties in the attempt to predict whether a molecular candidate would be able to 103 
achieve its biological target [17]. Optimization of both ligand potency and ADME(T) profile is absolutely 104 
required to translate promising molecular candidates to successful low-dose therapeutics. However, the 105 
success of this operation is not trivial, since the final result depends on factors such as the quality of the input 106 
data, as well as the adequacy and level of description of the physicochemical parameters used in the analysis. 107 
In fact, Gleeson and collaborators [18] have observed the existence of a diametrically opposed relationship 108 
between descriptors that efficaciously model drug potency and ADME(T) properties, making more 109 
challenging the drug discovery process.  110 
 111 
2. Lipophilicity in drug design 112 
The relevance of lipophilicity in understanding the pharmacological profile of drug-like compounds is 113 
widely recognized [19], as a broad variety of biodistribution and toxicological processes are ultimately 114 
related to the differential solubility of solutes in aqueous and non-aqueous environments. This is illustrated 115 
by Lipinski’s rule-of-five [20], which relates the drug-likeness of oral compounds with molecular weight, 116 
hydrogen bonding, and lipophilicity. Being a key property for the prediction of ADME(T) properties, this 117 
has stimulated the development of experimental and computational approaches to quantify the lipophilicity 118 
of a (bio)organic molecule.  119 
Experimentally, the lipophilicity of a molecule can be quantified by its partition coefficient (P), as this 120 
equilibrium thermodynamic property measures the ratio of concentrations of the compound between two 121 
immiscible solvents, generally water and n-octanol. In turn, the partition coefficient can be expressed in 122 
terms of the transfer free energy (∆𝐺𝑡𝑟
𝑜/𝑤) between the two solvents (Eq 1).  123 
 124 
∆𝐺𝑡𝑟
𝑜/𝑤 = −2.303 𝑅𝑇 𝑙𝑜𝑔𝑃          Eq 1 125 
Lipophilicity reflects the complex interplay between the intermolecular forces that dictate the differential 126 
solvation in the aqueous and organic phases. Accordingly, it can be factorized in terms of selected physico-127 
chemical properties of the compound that may be relevant for the preferential solvation in aqueous and non-128 
aqueous solvents, as shown in Eq 2 [21, and references therein].   129 
 130 
𝑙𝑜𝑔𝑃 = 𝑣𝑉 −  Λ + 𝐼 + 𝐼𝐸          Eq 2 131 
where v is a constant, V is the molar volume, which encompass the ability of the solute to elicit nonpolar 132 
interactions, Λ is related to the polarity of the compound, and finally I and IE accounts for the solute capacity 133 
to form ionic interactions, which favor partitioning into the aqueous phase, and for the contribution due to 134 
intramolecular effects, respectively. 135 
Let us note that lipophilicity and hydrophobicity, which are often used as equivalent concepts, are not strictly 136 
synonymous, the latter being in fact one of the contributions to molecular lipophilicity [22]. Thus, while 137 
hydrophobicity can be defined as the tendency of non-polar groups of a molecule to aggregate in order to 138 
minimize the unfavourable exposition to the surrounding polar (water) solvent, lipophilicity is a measure of 139 
the affinity of the molecule for the non-polar solvent in a biphasic system constituted by a polar and a non-140 
polar solvent. 141 
Lipophilicity affects a number of pharmacokinetic parameters (Figure 1). Low lipophilicity is responsible of 142 
high aqueous solubility, which is a key factor for drug-likeness, but an excessively low lipophilicity could 143 
compromise the ability of the drug to achieve the biological target. On the opposite site, highly soluble 144 
compounds possess poor permeability through biological membranes, limiting absorption along the 145 
gastrointestinal tract, or the transport across the blood-brain barrier. Therefore, optimal requirements for 146 
efficient solubility and permeability properties are inevitably enclosed in a very narrow range of 147 
lipophilicity. Another key aspect for drug-likeness is bioavailability, which is inversely correlated to low 148 
first-pass clearance. Once again, lipophilicity is crucial since high lipophilicity is associated to high 149 
clearance and low metabolic stability. Overall, a careful handling of lipophilicity is required to optimize 150 
compound availability at the biological target. 151 
 152 
Figure 1 here 153 
 154 
 155 
On the other hand, lipophilicity has rarely been used as the primary descriptor in ligand-receptor recognition. 156 
Indeed, following the IUPAC recommendation for the definition of a pharmacophore, it is defined as "the 157 
ensemble of steric and electronic features that is necessary to ensure the optimal supramolecular interactions 158 
with a specific biological target structure" [8]. This definition hides the key role played by (de)solvation in 159 
the recognition and binding of a drug-like compound to its macromolecular target [23], especially keeping in 160 
mind that the maximal achievable affinity that can be attained for target binding sites is largely influenced by 161 
nonpolar desolvation [24]. This is consistent with the concept that favourable drug binding is largely driven 162 
not only by the global lipophilicity of a compound, but more importantly by the spatial distribution of polar 163 
and apolar regions along the chemical skeleton. Thus, while apolar regions determine the binding affinity 164 
with complementary lipophilic regions of the binding site, polar interactions would provide 'anchor points' 165 
contributing to ligand specificity and/or directionality in the binding pocket, as well as to modulate binding 166 
kinetics of the ligand [25-30]. 167 
Taken together, these data suggest that a concomitant optimization of both pharmacokinetic profile and drug 168 
potency have to be done to obtain successful drug products. This is encoded in the concept of lipophilicity 169 
efficiency (LipE), which provides a metric that normalizes the potency (generally measured as Ki or IC50) of 170 
the ligand against a protein target for the lipophilicity of the compound [31-33]. This is achieved by 171 
substracting the logP (or the distribution coefficient for ionizable molecules, logD) from the negative 172 
logarithm of the potency (Eq 3).  173 
 174 
𝐿𝑖𝑝𝐸 =  − 𝑙𝑜𝑔 potency −  𝑙𝑜𝑔𝑃        Eq 3 175 
 176 
LipE can be useful to provide guidelines to study the simultaneous effects exerted by structural changes on 177 
potency and lipophilicity, which is central for drug design and lead optimization programmes, thus giving 178 
support to the formulation of the “lipophilic pharmacophore” concept.  179 
 180 
3. From empirical fragment/atom-based approaches to 3D structure-based methods to estimate lipophilicity 181 
Numerous efforts have been done to assess lipophilicity by means of experimental methods [34-36]. 182 
Similarly, a plethora of computational approaches for estimating logP have also been developed [37-42]. We 183 
limit ourselves to remark selected fundamental concepts, while the reader is addressed to the previously 184 
quoted reviews for detailed comparative analysis. 185 
Within the framework of substructure-based methods for logP estimation, fragmental and atom-based 186 
techniques follow a general additive scheme as shown in Eq 4, 187 
 188 
𝑙𝑜𝑔𝑃 =  𝑎𝑖𝑓𝑖 
𝑛
𝑖!! +  𝑏𝑗𝐹𝑗𝑚𝑗!!          Eq 4 189 
 190 
where logP is the sum of the weighted (𝑎𝑖) contribution of each fragment/atom (𝑓𝑖) and a correction factor 191 
(𝑏𝑗𝐹𝑗).  192 
Fragmental methods are illustrated by the work of Leo, Hansch and Elkins [43] as well as Nys and Rekker 193 
[44]. The former relies on the concept of substituent constant, which encodes the lipophilicity contribution of 194 
a chemical group or atom when it replaces an hydrogen atom in a reference compound, and the theoretical 195 
estimation of logPo/w follows an additivity scheme, named cLOGP. This method permits to extrapolate the 196 
partition coefficients starting from a list of experimentally fitted fragmental contributions to lipophilicity. An 197 
arbitrary set of interfragmental rules was then used to compile a database library of fragment-weighted 198 
lipophilicity contributions,. On the other hand, Nys and Rekker [44] introduced the concept of hydrophobic 199 
fragmental constant (f), which represents the lipophilicity contribution of a constituent part of a structure to 200 
the total lipophilicity of a given compound. Fragments range from atoms to heterocyclic rings, so that 201 
functional groups with direct contribution to resonance interactions were left intact, and are differentitated 202 
upon linkage to aliphatic and aromatic structures. The differences between experimental logP and the 203 
additive value estimated from the ∑f approach was accounted for by correction rules, reflecting factors such 204 
as the presence of vicinal electronegative centres in the chemical structure, aromatic condensation, cross-205 
conjugation or hydrogen-bonding [45]. 206 
An example of atom-based partitioning strategy was undertaken by Ghose and Crippen, who developed a 207 
procedure that combines lipophilicity contributions at an atomic level leading to the ALOGP method. This 208 
method encompassed a list of 120 atom types for carbon, hydrogen, oxygen, nitrogen, sulfur, and halogens 209 
[46-48]. An alternative strategy is the XLOGP method [49], which is based on the summation of atomic 210 
contributions derived from experimental lipophilicity data of 1831 organic molecules, and includes 211 
correction factors for some intramolecular interactions. 212 
In the last decades, the evolution of computer performances enabled the development of whole molecule-213 
based strategies to predict the lipophilicity by taking into account the three-dimensional structure of 214 
compounds, and thus the effect of molecular conformation. Among all the available techniques, the 215 
molecular lipophilicity potential (MLP) [51] offers an empirical quantitative 3D description of the 216 
lipophilicity potential from all the molecular fragments on the surrounding space of a compound. The MLP 217 
approach is then intended to model the lipophilic interactions between ligand and receptor as noted in Eq 5, 218 
 219 
𝑀𝐿𝑃𝑘 =  𝐹𝑖 𝑓 𝑑𝑖𝑘𝑁𝑖!!          Eq 5 220 
 221 
where 𝐹𝑖 is the lipophilic fragmental contribution and 𝑓 𝑑𝑖𝑘  is a distance function which depends on the 222 
separation between a given fragment (i) and any point on the molecular surface or volume (k).  223 
Molecular fields derived from the MLP potential have found a wide range of pharmaceutical applications, 224 
including the prediction of skin permeation and distribution of new chemical entities [50], modeling of 225 
peptides and proteins [52, 53], and structure-activity relationships studies [54]. 226 
The Hydrophobic INTeraction (HINT) method represents an alternative, promising strategy for the study of 227 
lipophilicity in biomolecular interactions [55, 56]. This method exploits a scale of hydrophobic fragments 228 
constants at the atomic level by means of an adaptation of the CLOGP method, which are then used to 229 
evaluate a pairwise interaction energy term (𝑏𝑖𝑗) between atoms i and j in the interacting partners according 230 
to Eq 6. 231 
 232 
𝑏𝑖𝑗 =  𝑎𝑖𝑆𝑖𝑎𝑗𝑆𝑗𝑇𝑖𝑗𝑅𝑖𝑗 +  𝑟𝑖𝑗           Eq 6 233 
 234 
where ai and Si are respectively the hydrophobic constant and the accessible surface area of the atom i, Tij is a 235 
logic function describing the character of interacting pairs (attraction or repulsion), and Rij and rij denote 236 
functions of the distance between atoms i and j, the former following an exponential form and the latter a 237 
Lennard-Jones implementation.  238 
Eq. 5 encodes the formalism of the “natural” HINT force-field, which has been used to explore a variety of 239 
applications in ligand-protein and protein-protein interactions [57-61].  240 
Other approaches have relied on molecular properties derived from quantum mechanical treatments of 241 
molecules. An early attempt is the work by Roger and Cammarata [62, 63], who related the logP of aromatic 242 
compounds with the charge density of both π and σ electron frameworks and the induced polarization. In a 243 
distinct approach, the BLOGP method relied on semiempirical AM1 calculations to derive geometrical and 244 
quantum chemical descriptors for the prediction of logP [64, 65]. In a similar approach, Clark and coworkers 245 
performed AM1 and PM3 calculations to derive a series of descriptors, including electrostatic potentials, 246 
total dipole moments, mean polarizabilities, surfaces, volumes and charges, which were used in the 247 
prediction of partition coefficients [66, 67].  248 
These efforts can also be exemplified with the concept of heuristic molecular lipophilic potential (HMLP) 249 
[68, 69]. In this approach, the lipophilic/hydrophilic features of a compound are determined from the 250 
analysis of the electrostatic potential computed at the molecular surface. To this end, a dimensionless 251 
distance-dependent screening function is used to compare the local electron density at the surface of a given 252 
atom with the electrostatic potential generated on the rest of atoms. The screening function, which was 253 
derived from statistical mechanical treatment of polar solvent molecules as dipoles, accounts for the 254 
influence exerted by the atomic descriptors of the electrostatic potential from surrounding atoms. Ultimately, 255 
such a comparison leads to the definition of an atomic lipophilicity index, which can adopt positive or 256 
negative values, reflecting the lipophilic and hydrophilic nature, respectively, of such an atom. 257 
Finally, a distinct approximation comes from the usage of solute-solvent correlation functions derived by 258 
using the Reference Interaction Site Model (RISM) as descriptors for QSAR studies. By using a classical 259 
statistical mechanics-based solvent model combined with machine learning, 1D solute-solvent correlation 260 
functions were used to predict Caco-2 cell permeabilities [70]. As an extension of this approach, Güssregen 261 
et al. proposed the Comparative Analysis of 3D-RISM Maps (CARMa) methodology [71]. In this 262 
computational strategy, the classical electrostatic and steric fields generally used in CoMFA are replaced by 263 
solute–solvent distribution functions determined from 3D-RISM computations, which are subsequently 264 
treated as descriptors to perform QSAR analysis. The method was validated using a set of serine protease 265 
inhibitors as a test system. 266 
Even though CARMa uses a statistical mechanics solvent model, the electrostatic and steric effects 267 
implemented in CoMFA cannot be directly captured. This issue has been recently addressed by solving 3D-268 
RISM equations for a solvent comprising CoMFA probes in aqueous solution, this extension being referred 269 
to as CARMa(electrolyte) [72]. The analysis performed for six protein–ligand systems reveals a small but 270 
consistent increase in prediction accuracy compared to CoMFA. 271 
 272 
4. Lipophilicity from QM continuum solvation methods. 273 
More elaborate methods for estimating the partition coefficients have been proposed in the framework of 274 
QM-based continuum solvation models [73, 74], which were developed with the aim of predicting the 275 
solvation free energy of solutes treating the solvent as a continuum polarizable medium. In spite of this 276 
rather crude approximation, these methods have proved to be a promising strategy that combines well 277 
established physical formalisms, a straightforward mathematical implementation, and a reduced 278 
computational cost, while predicting solvation free energies of (bio)organic compounds with chemical 279 
accuracy after a careful parameterization against experimental data [75-77]. Since a broad review of these 280 
formalisms and their applications exceeds the aims of this review, we limit ourselves to stress a selected set 281 
of recent studies addressing the potential impact of QM-based continuum methods in drug design.  282 
 283 
4.1 COSMO and COSMO-RS-based approaches 284 
In this context, the Continuum Solvation Model for Real Solvents (COSMO-RS) has been recently utilized 285 
to evaluate the similarity between molecules within the so-called COSMOsim method [78]. This method 286 
relies on the conductor-like screening model (COSMO) calculations to derive the so-called σ-profile of a 287 
given compound. The σ-profile collects the set of polarization charge densities generated on the surface 288 
patches of the molecule immersed in the solvent, which is treated as an ideal conductor. The one-289 
dimensional histogram distribution of the σ values for the whole set of surface elements enclosed in the 290 
molecular surface gives rise to a characteristic signature of the solute, which can be used to measure a σ-291 
profile-based similarity between compounds with application for the detection of bioisosteric fragments or 292 
molecules. In order to enhance the computational efficiency, the σ-profile of a new compound can be 293 
replaced with a composition of partial σ-profiles taken from similar fragments of precalculated molecules 294 
stored in a database using COSMOfrag [79].  295 
Since the σ-profile does not contain information about the spatial distribution of the polarization charge 296 
density, COSMOsim3D has been recently proposed to alleviate this limitation [80]. To this end, 297 
COSMOsim3D projects the surface charge density of each surface segment onto a regular 3D grid, so that 298 
each point of the grid has an associated local σ-profile. In other words, instead of generating a single 1D σ-299 
profile for the entire molecule, COSMOsim3D creates a local 1D σ-profile at each position of a regular 3D 300 
grid. This process leads to a four-dimensional histogram defined by the three Cartesian dimensions of the 301 
grid point and the local σ-profile as the fourth dimension. If calculated for two molecules, this strategy can 302 
be ultimately used to estimate their overall similarity. Furthermore, these local σ-profiles have been also 303 
used to generate molecular interactions fields for 3D-QSAR studies [81]. 304 
 305 
4.2 Fragmental lipophilicity model from the MST method: The Hyphar approach 306 
The Miertus-Scrocco-Tomasi (MST) solvation model has been used to develop 3D distribution patterns of 307 
lipophilicity, which in turn have been exploited in predicting molecular overlays and 3D-QSAR studies [82-308 
83]. The MST model is a parametrized version of the polarizable continuum model developed by Tomasi 309 
and coworkers [85, 86] at both semiempirical, Hartree-Fock and B3LYP levels [87-90] (for a review see 310 
[91]). From the solvation free energies in water and n-octanol, one can derive the n-octanol/water partition 311 
coefficient (Eq 1), which is a property of the whole molecule. Nevertheless, by decomposing the solvation 312 
free energy into atomic contributions, one can obtain the 3D profile of lipophilicity from the corresponding 313 
atomic contributions to the logP. For a molecule (M) containing N atoms, this is achieved by decomposing 314 
the logP (or the corresponding transfer free energy, Δ𝐺𝑡𝑟,𝑀
𝑜/𝑤 ) into electrostatic (𝑙𝑜𝑔𝑃𝑒𝑙𝑒,𝑖), cavitation (𝑙𝑜𝑔𝑃𝑐𝑎𝑣,𝑖) 315 
and van der Waals (𝑙𝑜𝑔𝑃𝑣𝑊,𝑖) components, which can be derived from the polar (Δ𝐺𝑒𝑙𝑒,𝑖
𝑜/𝑤) and non-polar 316 
(Δ𝐺𝑐𝑎𝑣,𝑖
𝑜/𝑤 ,  ΔG𝑣𝑊,𝑖
𝑜/𝑤 ) contributions to the solvation free energy (Eqs 7 and 8). 317 
 318 
Δ𝐺𝑡𝑟,𝑀
𝑜/𝑤 =  Δ𝐺𝑡𝑟,𝑖
𝑜/𝑤𝑁
𝑖!! =  Δ𝐺𝑒𝑙𝑒,𝑖
𝑜/𝑤 +  Δ𝐺𝑐𝑎𝑣,𝑖
𝑜/𝑤 +  Δ𝐺𝑣𝑊,𝑖
𝑜/𝑤𝑁
𝑖!!      Eq 7 319 
𝑙𝑜𝑔𝑃𝑀 =  𝑙𝑜𝑔𝑃𝑖
𝑁
𝑖!! =  𝑙𝑜𝑔𝑃𝑒𝑙𝑒,𝑖 +  𝑙𝑜𝑔𝑃𝑐𝑎𝑣,𝑖 +  𝑙𝑜𝑔𝑃𝑣𝑊,𝑖
𝑁
𝑖!!      Eq 8 320 
 321 
Partitioning of the electrostatic term into atomic contributions can be made resorting to a perturbation 322 
approximation of the coupling between the solute charge distribution and the solvent reaction field [92], 323 
leading to Eq 9. 324 
 325 
𝑙𝑜𝑔𝑃𝑒𝑙𝑒,𝑖
















Ψ!       Eq 9 326 
 327 
where  is the solute wave function in the gas phase, and K and L stand for the total number of reaction 328 
field charges in water ( ) and n-octanol ( ), located at positions  and .  329 
The atomic decomposition of the cavitation and van der Waals terms takes advantage of the linear 330 







𝑖!!           Eq 10 333 
𝑙𝑜𝑔𝑃𝑣𝑊,𝑖
𝑜/𝑤 =  𝑆𝑖Δ𝜉𝑜/𝑤𝑁𝑖!!           Eq 11 334 
 335 
where Δ𝐺 𝑃,𝑖
𝑜/𝑤 = Δ𝐺 𝑃,𝑖𝑤 − Δ𝐺 𝑃,𝑖𝑜 , Δ𝐺𝑃,𝑖 being the cavitation free energy of atom i, Δ𝜉
𝑜/𝑤 = 𝜉𝑤 − 𝜉𝑜, with  336 
𝜉𝑖 being the atomic surface tension, and 𝑆𝑖 denotes the contribution of atom i to the total molecular surface 337 
(𝑆𝑇).  338 
In contrast to the COSMO-RS-based approaches, which rely on the concept of σ-profile (see above), the 339 
MST-derived applications use the atomic contributions to the thermodynamic components of the differential 340 
solvation free energy in water and n-octanol, which are encoded under the partition coefficient between these 341 
two solvents. Accordingly, they take into account the effect of specific chemical features of the molecule, 342 
such as the existence of specific tautomers or conformational species, or the formation of specific 343 
intramolecular interactions (i.e., hydrogen bond), in the computation of the 3D distribution pattern of 344 
molecular lipophilicity.  345 
These patterns have been exploited to predict the chemical similarity between compounds [84]. By using the 346 
MST-based hydrophobic descriptors 𝑙𝑜𝑔𝑃𝑒𝑙𝑒,𝑖
𝑜/𝑤  and 𝑙𝑜𝑔𝑃𝑐𝑎𝑣,𝑖
𝑜/𝑤  , a computational procedure has been proposed to 347 
identify the molecular overlay that maximizes the lipophilic similarity. To this end, molecular similarity was 348 







following multipole expansions of the atomic lipophilic contributions. On the other hand, simple descriptors 350 
of the hydrogen-bond (HB) donor/acceptor character of atoms were used to complement the information 351 
about the chemical nature of polar atoms in a molecule (briefly, the current implementation assigns an 352 
arbitrary value of +1 to hydrogen atoms in HB donors, and -1 to N and O atoms that may act as acceptors). 353 
This choice obeys to the fact that the polar nature of hydrophilic groups cannot distinguish the HB 354 
donor/acceptor character, as this information is not implicitly encoded by the 𝑙𝑜𝑔𝑃𝑒𝑙𝑒,𝑖
𝑜/𝑤 term. Hydrophobic and 355 
HB properties are then projected into a 3D grid using the exponential function (Eq 12) implemented in 356 
CoMSiA [15], and then compared by means of the Tanimoto coefficient.  357 
 358 




          Eq 12 359 
 360 
The method was implemented in PharmScreen software [83,93] and was successfully used to evaluate the 361 
molecular overlay for a collection of 121 molecular systems compiled by AstraZeneca, denoted as the 362 
AstraZeneca Overlays Validation Test Set [94]. This set contains molecular overlays experimentally 363 
characterized for 119 targets, which were grouped in four categories according to the expected difficulty in 364 
predicting the experimental overlay: easy, moderate, hard, and unfeasible. The results pointed out that  365 
correct overlays were predicted for 94% (easy), 79% (moderate), and 54% (hard) of the cases. Moreover, the 366 
overall performance obtained from classical electrostatic/steric descriptors and from Hyphar ones was fairly 367 
similar for easy and moderate subsets, but the accuracy obtained with Hyphar for the subset of hard cases 368 
exceeded the performance obtained with electrostatic/steric properties. Finally, it was found that the similar 369 
performance of Hyphar and electrostatic/steric descriptors does not imply that they lead to identical overlays. 370 
Rather, the analysis of the predicted poses revealed that the degree of identity in molecular overlays was 371 
reduced with the increase in the difficulty of the target. Overall, these findings point out that Hyphar 372 
descriptors may be a valuable alternative for molecule superposition and virtual screening of chemical 373 
libraries, especially for targets that may be challenging for predictive molecular similarity techniques.  374 
On the other hand, the atom-centered MST-derived hydrophobic contributions have also been used as 375 
physicochemical descriptors to derive 3D-QSAR models using PharmQSAR [82]. MST/IEFPCM 376 
calculations were performed for 5 sets of compounds, including dopamine D2/D4 receptor antagonists, 377 
antifungal chromanones, glycogen synthase kinase-3 inhibitors, cruzain inhibitors, and thermolysin 378 
inhibitors. The compounds in these sets covered a wide range of variance in selected physicochemical 379 
properties (molecular weight, hydrogen-bond donor/acceptor, clogP, and number of rotatable bonds). The 380 
3D-QSAR models obtained with the hydrophobic pharmacophore (HyPhar) were found to have a predictive 381 
accuracy comparable to standard CoMFA and CoMSiA techniques. Moreover, Hyphar descriptors were also 382 
valuable to discriminate the selectivity of compounds acting as inhibitors of thrombin, trypsin, and factor Xa 383 
[83]. 384 
Overall, these findings support the usefulness of the MST-derived lipophilic descriptors as a valuable 385 
alternative to electrostatic/steric properties to carry out virtual screening of chemical libraries for molecular 386 
similarity, as well as to derive 3D lipophilic pharmacophores, thus providing valuable complementary 387 
information to gain insight into the molecular determinants of bioactivity. 388 
 389 
5. A comparative analysis between Hyphar and electrostatic/steric properties  390 
The strength of Hyphar descriptors in 3D-QSAR studies may be attributed to two major features. First, the 391 
concept of lipophilicity is very intuitive and widely accepted in medicinal chemistry. Second, the partitioning 392 
of lipophilicity, which reflects a property of the whole molecule, into atomic or fragmental contributions 393 
permits to obtain a graphical representation of the distribution pattern of polar and apolar regions adapted to 394 
the 3D structure of a given compound. In turn, this paves the way to rationalize the recognition between a 395 
small compound and its macromolecular target from the complementarity between hydrophilic and lipophilic 396 
groups of the ligand and the polar and apolar nature of the side chains of residues that shape the binding 397 
pocket. As an additional remark, let us note that resorting to Hyphar descriptors benefits from the accurate 398 
description of the molecular charge distribution that can be attained by QM methods, which may take into 399 
account the influence arising from the chemical features of the bioactive compound, such as the ionization 400 
state, the preference for a tautomeric species, and the adoption of a given conformational state representative 401 
of the binding mode of the ligand. 402 
Given the novelty of MST-based atomic lipophilicity contributions, it is nevertheless necessary to explore 403 
their suitability for 3D-QSAR studies. In this context, this section reports the results of a comparative 404 
analysis performed to calibrate the performance of Hyphar descriptors through comparison with 405 
electrostatic/steric ones. This analysis has been carried out using the comprehensive benchmark data set 406 
compiled by Sutherland and coworkers [95],  which comprises 113 angiotensin converting enzyme (ACE) 407 
inhibitors, 111 acetylcholinesterase (AChE) inhibitors, 147 ligands for benzodiazepine receptors (BZR), 282 408 
cyclooxygenase-2 (COX-2) inhibitors, 361 dihydrofolatereductase (DHFR) inhibitors, 66 glycogen 409 
phosphorylase b (GPB) inhibitors, 74 thermolysin (THER) inhibitors, and 87 thrombine (THR) inhibitors. 410 
Accordingly, the CoMFA/CoMSiA results reported in ref. 95 were compared with the 3D-QSAR models 411 
obtained using Hyphar descriptors, which combine both “polar” (𝑙𝑜𝑔𝑃!"!,!) and “non-polar” (𝑙𝑜𝑔𝑃!"#,!) 412 
hydrophobic contributions (see above). To this end, the atomic electrostatic and non-electrostatic 413 
components of the lipophilicity were used to generate the molecular fields through projection into a grid that 414 
encloses the set of aligned compounds using a similarity index function (see [82] for further details). For the 415 
sake of comparison, the original molecular geometries and protonation states of compounds were kept in this 416 
study. All the details about models generation, grid dimensions and points, training/test sets, and related 417 
activity ranges for the eight sets compiled by Sutherland are reported in Supplementary Material (Tables S1-418 
S3). 419 
As a preliminary step, the effect of the QM method selected to derive the hydrophobic contributions on the 420 
performance of the 3D-QSAR Hyphar models was evaluated for a subset of four systems (D2 inhibitors, 421 
antifungal chromanones, GSK3-β and cruzain inhibitors) taken from our previous study [82]. To this end, 422 
Hyphar descriptors were derived from continuum computations performed with the MST version 423 
parametrized for the semiempirical RM1 method [96], and alternatively with the version parametrized at the 424 
B3LYP/6-31G(d) level [90]. Comparison of the statistical parameters obtained for the subset of training and 425 
test compounds defined for each molecular system is shown in Table 1.  426 
 427 
Table 1. Statistical parameters of the 3D-QSAR HyPhar models obtained from MST/B3LYP and MST/RM1 428 
calculations for the four sets of compounds.a 429 
 430 
 Training set Test set  Field (%) 
System r2 q2 S Spress r2 S Nc  Elec Non-elec 
D2 
MST/B3LYP 0.94 0.77 0.31 0.60 0.78 0.57 3 68.6 31.4 
MST/RM1 0.93 0.74 0.28 0.65 0.71 0.63 3 70.9 29.1 
Chromanones  
MST/B3LYP 0.77 0.51 0.49 0.29 0.81 0.20 3 34.3 65.7 
MST/RM1 0.76 0.42 0.51 0.32 0.66 0.82 3 42.1 57.9 
GSK3  
MST/B3LYP 0.91 0.80 0.12 0.19 0.79 0.21 3 54.5 45.5 
MST/RM1 0.91 0.82 0.30 0.18 0.79 0.21 5 64.7 35.3 
Cruzain  
MST/B3LYP 0.81 0.50 0.31 0.51 0.69 0.47 2 53.0 47.0 
MST/RM1 0.91 0.65 0.31 0.44 0.70 0.46 3 58.4 41.6 
     431 
a See [92] for a proper description of the molecular sets. Nc denotes the number of PLS components in the 432 
best 3D-QSAR model, and the terms Elec and Non-elec stand for the fraction (in percentage) of electrostatic 433 
(𝑙𝑜𝑔𝑃!"!,!) and non-electrostatic (𝑙𝑜𝑔𝑃!"#,!) hydrophobic contributions to the final model.  434 
 435 
The results reveal that there is large resemblance in the overall performance of the 3D-QSAR models 436 
obtained from MST/RM1 and MST/B3LYP Hyphar descriptors for all data sets. This finding is remarkable, 437 
since 3D-QSAR models derived from the RM1 hydrophobic descriptors compare well with the performance 438 
obtained at the B3LYP level, but at a much lower computational cost, making the usage of semiempirical 439 
methods highly attractive for the study of large libraries of drug-like compounds. Accordingly, the 440 
computationally less demanding RM1 method seems to be a promising choice for 3D-QSAR studies with 441 
Hyphar parameters. 442 
On the basis of these results, the benchmark data set reported by Sutherland and coworkers [95] was 443 
examined using the MST/RM1 Hyphar descriptors. The 3D-QSAR Hyphar models were compared with the 444 
CoMFA/CoMSIA results reported in [95], which were obtained by using electrostatic potential-fitted charges 445 
at the MNDO level, but for the THER set, where Gasteiger-Marsili charges were used. For the sake of 446 
comparison, an additional model, denoted CoMFA (RM1), which exploits RM1 electrostatic-potential fitted 447 
partial charges in conjunction with an steric field obtained from the Lennard-Jones potential with a positively 448 
charged C.3 atom probe, was also examined. This model, therefore, is intended to explore the efficiency of 449 
RM1-based partial charges in defining electrostatic features of molecules at the atomic level. 450 
Table 2 shows the statistical parameters of the 3D-QSAR models. In general, similar performances were 451 
obtained for the different 3D-QSAR models determined for molecules in the training test included in a given 452 
system, as noted in the large resemblance between the statistical values of the regression (r2) and cross-453 
validation (q2) models. The same trend can be observed for the test set compounds, although a small 454 
improvement was found for CoMFA (RM1) and Hyphar models in GPB and THERM systems compared to 455 
reference CoMFA/CoMSiA models. In addition, a higher level of accuracy was also achieved by the models 456 
derived from RM1 calculations since the number of outliers in the test set was lower than in classical 457 
CoMFA/CoMSIA (Supplementary Material, Table S4). On the other hand, both BZR and COX2 were 458 
confirmed to be challenging systems for QSAR modelling, as already noted by Sutherland and coworkers 459 
[95]. For instance, in case of COX2, part of the reason for the poor predictive behaviour may probably be 460 
ascribed to the fact that training and test set cover different ranges of in the property space. 461 
 462 
Table 2. Statistical parameters obtained for CoMFA and CoMSiA models reported in [95] with the results 463 
determined by using COMFA (RM1) and Hyphar models in this study for the eight molecular systems 464 
(ACE, AChE, BZR, COX2, DHFR, GPB, THERM and THR).a 465 
 Training set Test set  Field (%) 
System r2 q2 S Spress r2 S Nc * Ele N-Ele HB 
ACE b 
CoMFA 0.80 0.68 1.04 - 0.49/0.55 1.54/1.47 3 - - - 
CoMSiA 0.76 0.65 1.15 - 0.52/0.58 1.48/1.41 3 - - - 
CoMFA (RM1) 0.82 0.67 0.42 1.37 0.54/0.61 1.45/1.32 3 29.4 70.6 - 
Hyphar 0.75 0.64 0.51 1.43 0.42/0.62 1.62/1.35 2 28.8 53.5 17.7 
AChE   
CoMFA 0.88 0.52 0.41 - 0.47/0.56 0.95/0.87 5 - - - 
CoMSiA 0.86 0.48 0.45 - 0.44/0.60 0.98/0.81 6 - - - 
CoMFA (RM1) 0.90 0.54 0.32 0.85 0.35/0.52 1.07/0.86 6 20.0 80.0 - 
Hyphar 0.76 0.45 0.50 0.92 0.65 0.78 4 64.1 18.7 17.2 
BZR  
CoMFA 0.61 0.32 0.41 - 0.00/0.18 0.97/0.81 3 - - - 
CoMSiA 0.62 0.41 0.41 - 0.08/0.30 0.93/0.75 3 - - - 
CoMFA (RM1) 0.60 0.36 0.64 0.53 0.21/0.21 0.81/0.80 3 30.5 69.5 - 
Hyphar 0.67 0.37 0.58 0.54 0.00/0.02 0.91/0.86 6 48.8 16.7 34.5 
COX2  
CoMFA 0.70 0.49 0.56 - 0.29/0.37 1.24/1.09 5 - - - 
CoMSIA 0.69 0.43 0.56 - 0.03/0.22 1.44/1.20 6 - - - 
CoMFA (RM1) 0.74 0.51 0.52 0.72 0.19/0.34 1.20/1.07 5 28.6 71.4 - 
Hyphar 0.60 0.52 0.63 0.71 0.26/0.40 1.15/0.99 3 85.4 4.3 10.3 
DHFR 
CoMFA 0.79 0.65 0.59 - 0.59/0.70 0.89/0.73 5 - - - 
CoMSiA 0.76 0.63 0.62 - 0.52/0.63 0.96/0.81 5 - - - 
RM1 CoMFA 0.81 0.67 0.44 0.73 0.42/0.55 1.04/0.91 4 17.7 82.3 - 
Hyphar 0.72 0.63 0.53 0.78 0.53/0.56 0.94/0.89 5 36.2 38.8 25.0 
GPB  
CoMFA 0.84 0.42 0.43 - 0.42/0.37 0.94/0.70 4 - - - 
CoMSiA 0.78 0.43 0.50 - 0.46/0.34 0.90/0.82 4 - - - 
CoMFA (RM1) 0.88 0.43 0.36 0.85 0.51 0.89 4 24.4 75.6 - 
Hyphar 0.83 0.54 0.42 0.75 0.71 0.68 3 52.0 2.7 45.3 
THERM c 
CoMFA 0.94 0.51 0.55 1.54 0.60 1.26 7 - - - 
CoMSiA 0.85 0.54 0.73 - 0.36/0.46 1.87/1.60 6 - - - 
CoMFA (RM1) 0.90 0.46 0.33 1.57 0.51/0.66 1.39/1.18 5 25.5 74.5 - 
Hyphar 0.84 0.49 0.41 1.51 0.67 1.13 4 37.9 25.5 36.6 
THR d 
CoMFA 0.86 0.59 0.36 - 0.54/0.73 1.59/0.56 4 - - - 
CoMSiA 0.88 0.62 0.34 - 0.55/0.62 0.76/0.66 5 - - - 
CoMFA (RM1) 0.89 0.59 0.33 0.64 0.45/0.58 0.86/0.82 5 16.0 84.0 - 
Hyphar 0.87 0.64 0.37 0.59 0.53/0.56 0.79/0.74 4 37.5 41.7 20.8 
 466 
a For test sets compounds, statistical parameters (r2 and S) with (left) and without (right) outliers (i.e.,  467 
compounds with residuals higher than 2.5-fold the standard deviation) are indicated. The number of outliers 468 
for each system is reported in Supplementary Material (Table S4). 469 
b mol0088 (original file name mol_17) was excluded because it contains iodine atom. 470 
c Partition between training and test sets made as indicated in [15].  471 
d mol0088 (original file name 82) was excluded due to problems with the input geometry. 472 
 473 
The predictive performance of the models was also examined by analyzing their capacity to discriminate 474 
between active and inactive compounds. To this end, for each molecular system the compounds in the test 475 
set were ranked according to their experimental potency: “active/positive” (P) and “inactive/negative” (N) 476 
were categorized by applying a threshold value of 6.0 (in pIC50/pKi units). Then, test set compounds with a 477 
predicted pIC50/pKi value larger than the threshold value were considered “actives/positives” (TP), whereas 478 
compounds with a predicted pIC50/pKi value lower than the threshold were considered “inactives/negatives” 479 
(TN). For each molecular system, the number of P, N, TP and TN compounds, as well as false positives (FP) 480 
and false negatives (FN) are compiled in Supplementary Material (Table S5). In turn, these values were used 481 
to identify correctly negative (specificity or TNR; in green in Figure 2) and positive (sensitivity or TPR; in 482 
blue in Figure 2) compounds, and to reduce the false negative rate (“fall-out” or FPR; in red in Figure 2) by 483 
applying Eqs. 13-15.  484 
 485 




         Eq. 13 486 




         Eq. 14 487 




= 1 − 𝑇𝑁𝑅        Eq. 15 488 
 489 
Figure 2 here 490 
 491 
These parameters, which can vary from 0 to 1, can be considered a measure of the predictive performance of 492 
the model. According to this classification, a model can be considered good if it has high 493 
specificity/sensitivity and low fall-out values. Nevertheless, this analysis requires a balanced partition of 494 
active and inactive compounds in the set of compounds, a requirement that is not fulfilled in the case of BZR 495 
and GPB systems, since only one inactive and one active compound are present in these two sets, 496 
respectively. Accordingly, the results obtained for BZR and GPB should be excluded from the analysis. For 497 
the rest of molecular systems, both CoMFA (RM1) and Hyphar models exhibit generally similar trends 498 
(Figure 2). The Hyphar model has a slightly better performance in sensitivity/specificity and fall-out values 499 
for AchE, THERM and THR systems, whereas the opposite trend in found for CoMFA (RM1) in ACE and 500 
COX2. 501 
Finally, the ability of CoMFA (RM1) and Hyphar models to rank the compounds according to their potency 502 
was also examined (Figure 3). To this end, the Spearman (Rs) coefficient for the first (Q1; in green), second 503 
(Q2; in blue) and third (Q3; in red) quartiles, which would encompass molecules with highest, medium and 504 
low activity/affinity, were determined for the test set compounds in each system. Although there is a notable 505 
resemblance in the general trends obtained for CoMFA (RM1) and Hyphar models, slightly better 506 
performances (higher Rs values) are observed for Hyphar models, especially for compounds of higher 507 
activity/affinity (Q1/Q2), whereas the differences are less pronounced for compounds in Q3, probably due to 508 
the larger noise associated to the biological activity low active compounds. 509 
 510 
Figure 3 here 511 
 512 
Overall, the results obtained for the benchmark systems reveal that the Hyphar descriptors yield 3D-QSAR 513 
models with an overall performance that compares with the results obtained using standard 514 
CoMFA/CoMSiA. Hyphar models also seem to be more effective in locating (high sensibility) and ranking 515 
(high Rs) true positives, especially in regions of high and medium activity/affinity.  516 
 517 
6. Final consideration and perspectives.  518 
The concept of pharmacophore is essential to disclose the key features that dictate the interaction between 519 
ligand and receptor. Hence, it represents an important tool to identify guidelines valuable in computer-aided 520 
drug design, covering a variety of applications such as molecular similarity, virtual screening, ligand 521 
optimization, scaffold hopping, as well as modeling of ADME(T) properties and target identification. The 522 
descriptive and predictive power of pharmacophores depends on the quality and adequacy of molecular 523 
properties used to disclose the hidden relationship between activity and chemical structure. In the last 524 
decades several strategies were developed to derive descriptors capable of capturing the chemical features 525 
relevant for drug design, including the application of descriptors derived from QM methods coupled to 526 
continuum solvation models. 527 
Although fundamental for the activity of drug-like compounds, inclusion of lipophilicity as a major 528 
descriptor has revealed more elusive, possibly due to the complexity of the chemical processes encompassed 529 
by this concept, or the difficulty to find a rigorous formalism to reduce it to atomic contributions since 530 
lipophilicity reflects a property of the whole molecule. In this context, it is worth stressing the efforts in 531 
deriving tools such as MLP [50] and HINT [55, 56], where the molecular lipophilicity was treated by means 532 
of empirical atomic contributions, and hence enabling the analysis of the 3D distribution of polar/apolar 533 
regions along the chemical scaffold to provide a novel interpretation to the molecular determinants 534 
responsible of biological activity. 535 
QM-based continuum solvation methods are a promising strategy for deriving 3D descriptors, such as 536 
COSMO-RS-based σ-profiles [78-81] or MST-derived 3D lipophilicity patterns [82-84,97-99], which in turn 537 
may be exploited in computer-aided drug design. The set of studies reported up to now for a variety of 538 
benchmark datasets, covering both measurements of molecular similarity for aligned compound or the 539 
derivation of 3D-QSAR models, are encouraging. In general, the statistical performance of these QM-based 540 
descriptors compares well with the results obtained from classical approaches, generally combining 541 
electrostatic and steric fields, as illustrated in the comparative analysis reported here for the sets of 542 
compounds considered by Sutherland and coworkers [95]. At least in part, this may be due to the limitations 543 
of electrostatic/steric descriptors for describing enthalpy and entropy contributions to the binding affinity. On 544 
the other hand, QM-based approaches permit to account directly for the specific features of the bioactive 545 
species of the ligand, including effects attributable to ionization, tautomerism, or the specific conformation, 546 
which may be advantageous compared to generic descriptors derived from empirical contributions. These 547 
computational approaches benefit from the usage of lipophilicity, a property widely used in drug design, 548 
easy to interpret by medicinal chemists, and linked to a physicochemical property that can be measured 549 
experimentally. Through partitioning of the molecular lipophilicity into atomic contributions, novel 550 
fractional models that account for the 3D lipophilicity pattern of compounds can then be exploited in 551 
computer-assisted drug design.  552 
Overall, the analysis of structure-activity relationships in terms of the lipophilic/hydrophilic balance may 553 
provide a useful signature to complement studies performed with electrostatic/steric properties. In this sense, 554 
the QM MST-based hydrophobic descriptors are valuable in predicting molecular overlays and elucidating 555 
molecular similarity patterns. The higher descriptive quality of these descriptors could thus offer interesting 556 
clues in searching for novel bioactive compounds, especially for challenging targets. 557 
 558 
Executive summary.  559 
! All biological and biochemical processes are driven by the general concept of host-guest 560 
complementarity. Accordingly, an essential but effective description of the “guest” is required for a 561 
successful prediction of “host” recognition. 562 
! The pharmacophore concept is a fundamental cornerstone in drug discovery, as it accounts for the 563 
common interaction features of a group of compounds towards their target structure, playing a 564 
critical role in determining the success of in silico techniques. 565 
! Optimized descriptors able to model both pharmacokinetics and pharmacodynamics properties in 566 
drug design are not easily achievable, and the use of sub-optimal physicochemical parameters may 567 
be a more effective strategy. 568 
! Besides the relevance in predicting ADME(T) properties, lipophilicity exerts a pivotal role in 569 
accounting for the maximal achievable affinity that can be attained between ligand and receptor. 570 
! The usage of lipophilicity descriptors may offer novel opportunities to disclose the underlying 571 
relationships between chemical features and biological activity. In this context, the availability of 572 
refined version of QM-based continuum solvation models may be an effective strategy for deriving 573 
novel descriptors well suited for drug design. 574 
! In 3D-QSAR studies, the MST-derived Hyphar descriptors have been shown to provide models for 575 
structure-activity relationships with a predictive accuracy comparable to CoMFA/CoMSiA 576 
techniques based on electrostatic/steric parameters. 577 
! The Hyphar descriptors are also a valuable alternative for molecule superposition and virtual 578 
screening of chemical libraries, especially for targets that may be challenging for predictive 579 
molecular similarity techniques. 580 
! The availability of “polar” and “non-polar” fractional descriptors obtained from MST-based 581 
continuum solvation models may be valuable to explore the molecular determinants of bioactivity, 582 
providing complementary interpretations to classical descriptors in the rational design of novel 583 
compounds.  584 
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